You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Austin, Texas-based molecular diagnostics firm logged $60.6 million in Q3 revenues as its system sales shot up 26 percent to $9.6 million.
The results confirm previous findings suggesting molecular tests may not be the best tool guide treatment for Clostridium difficile infection, and toxin assays are necessary.
Using Quanterix's Simoa technology, the group developed assays to detect C. diff toxins with a high degree of sensitivity and specificity.
The assay is the first on the firm's isothermal nucleic acid amplification-based platform.
The test adds to a growing menu of approved assays for the cobas 4800 system.
Researchers from the Public Health Agency of Sweden have developed an approach for typing Clostridium difficile isolates based on their patterns of high-molecular weight proteins.
Diagnostics revenues at the company jumped 5 percent organically driven in part by a 16 percent increase in sales of illumigene molecular diagnostic products.
The waiver opens up a significant new opportunity for Alere within the physician office market, according to a company executive.
The investment bank downgraded Meridian Bioscience from a prior Market Perform rating, noting challenges to its molecular diagnostics business.
The editorial board of the Pittsburgh Post-Gazette says other lawmakers should take Florida's approach and provide additional protections against genetic discrimination.
The Hill reports 17 states and the District of Columbia are suing over a new policy that would strip international students of their visas if they only attend classes online.
Centers for Disease Control and Prevention employees call on the agency to label racism a public health crisis and examine its own policies, NPR reports.
In PNAS this week: genetic evidence for Inca resettlement, analysis of spermatogonial stem cell transcriptomes, and more.